TY - JOUR
T1 - Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy
T2 - Results from a Large Cohort Study
AU - Nota, Nienke M
AU - Wiepjes, Chantal M
AU - de Blok, Christel J M
AU - Gooren, Louis J G
AU - Kreukels, Baudewijntje P C
AU - den Heijer, Martin
PY - 2019/3/12
Y1 - 2019/3/12
N2 - In hypogonadal/postmenopausal individuals, hormone therapy has been associated with an increased risk for cardiovascular events (CVEs). A steeply growing population that often receives exogenous hormones is transgender individuals. Although transgender individuals hypothetically have an increased risk of CVEs, there is little known about the occurrence of CVEs in this population.1 Therefore, we determined the incidences of acute/spontaneous strokes (ischemic/hemorrhagic, transient ischemic attack, or subarachnoid hemorrhage), myocardial infarctions (MIs), and venous thromboembolic events (VTEs) in transwomen and transmen receiving transgender hormone therapy (THT). Subsequently, we compared these incidences with those reported in women and men from the general population.
AB - In hypogonadal/postmenopausal individuals, hormone therapy has been associated with an increased risk for cardiovascular events (CVEs). A steeply growing population that often receives exogenous hormones is transgender individuals. Although transgender individuals hypothetically have an increased risk of CVEs, there is little known about the occurrence of CVEs in this population.1 Therefore, we determined the incidences of acute/spontaneous strokes (ischemic/hemorrhagic, transient ischemic attack, or subarachnoid hemorrhage), myocardial infarctions (MIs), and venous thromboembolic events (VTEs) in transwomen and transmen receiving transgender hormone therapy (THT). Subsequently, we compared these incidences with those reported in women and men from the general population.
KW - Hormones
KW - Myocardial infarction
KW - Stroke
KW - Transgender persons
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85062850071&partnerID=8YFLogxK
U2 - https://doi.org/10.1161/CIRCULATIONAHA.118.038584
DO - https://doi.org/10.1161/CIRCULATIONAHA.118.038584
M3 - Letter
C2 - 30776252
SN - 0009-7322
VL - 139
SP - 1461
EP - 1462
JO - Circulation
JF - Circulation
IS - 11
ER -